Epigallocatechin-3-gallate suppresses the growth of human osteosarcoma by inhibiting the Wnt/β-catenin signalling pathway

References

• Kobayashi E, Hornicek FJ, Duan Z. MicroRNA involvement in osteosarcoma. Sarcoma. 2012;2012:359739.
   PubMedGoogle Scholar
• Zhao X, Wu Q, Gong X, et al. Osteosarcoma: a review of current and future therapeutic approaches. Biomed Eng Online. 2021;20:24.
   PubMed Web of Science ®Google Scholar
• Jafari F, Javdansirat S, Sanaie S, et al. Osteosarcoma: a comprehensive review of management and treatment strategies. Ann Diagn Pathol. 2020;49:151654.
   PubMed Web of Science ®Google Scholar
• Marchandet L, Lallier M, Charrier C, et al. Mechanisms of resistance to conventional therapies for osteosarcoma. Cancers (Basel). 2021;13:683.
   PubMed Web of Science ®Google Scholar
• Niedzwiecki A, Roomi MW, Kalinovsky T, et al. Anticancer efficacy of polyphenols and their combinations. Nutrients. 2016;8:552.
   PubMed Web of Science ®Google Scholar
• Fujiki H, Watanabe T, Sueoka E, et al. Cancer prevention with green tea and its principal constituent, EGCG: from early investigations to current focus on human cancer stem cells. Mol Cells. 2018;41:73–82.
   PubMed Web of Science ®Google Scholar
• Bag A, Bag N. Tea polyphenols and prevention of epigenetic aberrations in cancer. J Nat Sci Biol Med. 2018;9:2–5.
   PubMedGoogle Scholar
• Lambert JD. Does tea prevent cancer? Evidence from laboratory and human intervention studies. Am J Clin Nutr. 2013;98:1667S–75S.
   PubMed Web of Science ®Google Scholar
• Lambert JD, Elias RJ. The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch Biochem Biophys. 2010;501:65–72.
   PubMed Web of Science ®Google Scholar
• Lee KJ, Lee SH. Extraction behavior of caffeine and EGCG from green and black tea. Biotechnol Bioprocess Eng. 2008;13:646–649.
   Web of Science ®Google Scholar
• Shi J, Liu F, Zhang W, et al. Epigallocatechin-3-gallate inhibits nicotine-induced migration and invasion by the suppression of angiogenesis and epithelial-mesenchymal transition in non-small cell lung cancer cells. Oncol Rep. 2015;33:2972–2980.
   PubMed Web of Science ®Google Scholar
• Ni CX, Gong H, Liu Y, et al. Green tea consumption and the risk of liver cancer: a meta-analysis. Nutr Cancer. 2017;69:211–220.
   PubMed Web of Science ®Google Scholar
• Moses MA, Henry EC, Ricke WA, et al. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model. Cancer Prev Res (Phila). 2015;8:249–257.
   PubMed Web of Science ®Google Scholar
• Cerezo-Guisado MI, Zur R, Lorenzo MJ, et al. Implication of Akt, ERK1/2 and alternative p38MAPK signalling pathways in human colon cancer cell apoptosis induced by green tea EGCG. Food Chem Toxicol. 2015;84:125–132.
   PubMed Web of Science ®Google Scholar
• Gu JJ, Qiao KS, Sun P, et al. Study of EGCG induced apoptosis in lung cancer cells by inhibiting PI3K/Akt signaling pathway. Eur Rev Med Pharmacol Sci. 2018;22:4557–4563.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang XQ, Zhang Q, et al. (-)-Epigallocatechin-3-Gallate inhibits colorectal cancer stem cells by suppressing Wnt/beta-Catenin pathway. Nutrients. 2017;9:572.
   PubMed Web of Science ®Google Scholar
• Huang Y, Chen J, Yang S, et al. Cinnamaldehyde inhibits the function of osteosarcoma by suppressing the Wnt/beta-Catenin and PI3K/Akt signaling pathways. Drug Des Devel Ther. 2020;14:4625–4637.
   PubMed Web of Science ®Google Scholar
• Wang N, Yang S, Tan T, et al. Tetrandrine suppresses the growth of human osteosarcoma cells by regulating multiple signaling pathways. Bioengineered. 2021;12:5870–5882.
   PubMed Web of Science ®Google Scholar
• Wang N, Liu W, Tan T, et al. Notch signaling negatively regulates BMP9-induced osteogenic differentiation of mesenchymal progenitor cells by inhibiting JunB expression. Oncotarget. 2017;8:109661–109674.
   PubMedGoogle Scholar
• Huang Y, Wu S, Zhang Y, et al. Antitumor effect of triptolide in T-cell lymphoblastic lymphoma by inhibiting cell viability, invasion, and epithelial-mesenchymal transition via regulating the PI3K/AKT/mTOR pathway. Onco Targets Ther. 2018;11:769–779.
   PubMed Web of Science ®Google Scholar
• Aggarwal V, Tuli HS, Tania M, et al. Molecular mechanisms of action of epigallocatechin gallate in cancer: recent trends and advancement. Semin Cancer Biol. 2020. DOI:10.1016/j.semcancer.2020.05.011
   Web of Science ®Google Scholar
• Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. 2011;82:1807–1821.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Owusu L, Duan W, et al. Anti-metastatic and differential effects on protein expression of epigallocatechin-3-gallate in HCCLM6 hepatocellular carcinoma cells. Int J Mol Med. 2013;32:959–964.
   PubMed Web of Science ®Google Scholar
• Huang YJ, Wang KL, Chen HY, et al. Protective effects of epigallocatechin gallate (EGCG) on endometrial, breast, and ovarian cancers. Biomolecules. 2020;10:1481.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Duan W, Owusu L, et al. Epigallocatechin-3-gallate induces the apoptosis of hepatocellular carcinoma LM6 cells but not non-cancerous liver cells. Int J Mol Med. 2015;35:117–124.
   PubMed Web of Science ®Google Scholar
• Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395–417.
   PubMed Web of Science ®Google Scholar
• Wu D, Liu Z, Li J, et al. Epigallocatechin-3-gallate inhibits the growth and increases the apoptosis of human thyroid carcinoma cells through suppression of EGFR/RAS/RAF/MEK/ERK signaling pathway. Cancer Cell Int. 2019;19:43.
   PubMed Web of Science ®Google Scholar
• Zhong X, Liu M, Yao W, et al. Epigallocatechin-3-Gallate attenuates microglial inflammation and neurotoxicity by suppressing the activation of canonical and noncanonical inflammasome via TLR4/NF-kappaB pathway. Mol Nutr Food Res. 2019;63:e1801230.
   PubMed Web of Science ®Google Scholar
• Shang S, Hua F, Hu ZW. The regulation of beta-catenin activity and function in cancer: therapeutic opportunities. Oncotarget. 2017;8:33972–33989.
   PubMedGoogle Scholar
• Chen D, Wan SB, Yang H, et al. EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment. Adv Clin Chem. 2011;53:155–177.
   PubMed Web of Science ®Google Scholar
• Gu L, Lingeman R, Yakushijin F, et al. The anticancer activity of a first-in-class small-molecule targeting PCNA. Clin Cancer Res. 2018;24:6053–6065.
   PubMed Web of Science ®Google Scholar
• Chen C, Xie L, Ren T, et al. Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021;500:1–10.
   PubMed Web of Science ®Google Scholar